The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy

Bibliography

• Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28(10):721-6
   PubMed Web of Science ®Google Scholar
• Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977;55(1):48-51
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253(5022):905-9
   PubMed Web of Science ®Google Scholar
• Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369(6483):756-8
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149(2):274-93
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol 2012;4:2
   PubMed Web of Science ®Google Scholar
• Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell 2011;144(5):757-68
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10(11):868-80
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22(2):159-68
   PubMed Web of Science ®Google Scholar
• Guertin DA, Stevens DM, Saitoh M, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15(2):148-59
   PubMed Web of Science ®Google Scholar
• Nardella C, Carracedo A, Alimonti A, et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal 2009;2(55):ra2
   PubMedGoogle Scholar
• Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005;102(23):8204-9
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Alain T, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010;328(5982):1172-6
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7(10):763-77
   PubMed Web of Science ®Google Scholar
• Düvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010;39(2):171-83
   PubMed Web of Science ®Google Scholar
• Masri J, Bernath A, Martin J, et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 2007;67(24):11712-20
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Judson I, Verweij J, et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced, soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 2012;23(Suppl 9):LBA7
   Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879-86
   PubMed Web of Science ®Google Scholar
• Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013;382(9896):973-83
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Suzuki S, Sato E, et al. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol 2009;22(10):1328-40
   PubMed Web of Science ®Google Scholar
• Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep 2013;15(4):386-95
   PubMedGoogle Scholar
• Ríos-Moreno MJ, Jaramillo S, Díaz-Delgado M, et al. Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res 2011;31(9):3019-25
   PubMed Web of Science ®Google Scholar
• Sápi Z, Füle T, Hajdu M, et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol 2011;20(1):22-33
   PubMed Web of Science ®Google Scholar
• Quattrone A, Wozniak A, Dewaele B, et al. PTEN inactivation in gastrointestinal stromal tumors (GIST): possible relevance for treatment of imatinib-resistant disease. Mol Cancer Ther 2011;10(11 Suppl):A166
   Google Scholar
• Daniels M, Lurkin I, Pauli R, et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 2011;312(1):43-54
   PubMed Web of Science ®Google Scholar
• Wang CM, Huang K, Zhou Y, et al. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. J Cancer Res Clin Oncol 2010;136(7):1065-71
   PubMedGoogle Scholar
• Yang J, Ikezoe T, Nishioka C, et al. Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int J Cancer 2012;130(4):959-66
   PubMed Web of Science ®Google Scholar
• Setsu N, Yamamoto H, Kohashi K, et al. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer 2012;118(6):1637-48
   PubMed Web of Science ®Google Scholar
• Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007;13(6):748-53
   PubMed Web of Science ®Google Scholar
• Wong TF, Takeda T, Li B, et al. Curcumin targets the AKT-mTOR pathway for uterine leiomyosarcoma tumor growth suppression. Int J Clin Oncol 2014;19(2):354-63
   PubMedGoogle Scholar
• Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42(8):715-21
   PubMed Web of Science ®Google Scholar
• Demicco EG, Torres KE, Ghadimi MP, et al. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol 2012;25(2):212-21
   PubMed Web of Science ®Google Scholar
• Smith KB, Tran LM, Tam BM, et al. Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition. Am J Pathol 2013;182(4):1400-11
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Dell’Aglio C, Basiricò M, et al. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res 2013;19(8):2117-31
   PubMed Web of Science ®Google Scholar
• Kiezun A, Janeway K, Tonzi P, et al. Next generation sequencing of osteosarcoma identifies the PI3K/mTOR pathway as a unifying vulnerability to be exploited for targeted therapy [abstract 3563T]. Presented at the 63rd Annual Meeting of The American Society of Human Genetics; 24 October 2013; Boston, MA
   Google Scholar
• Zhou Q, Deng Z, Zhu Y, et al. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis. Med Oncol 2010;27(4):1239-45
   PubMed Web of Science ®Google Scholar
• Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272(49):30822-7
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65(9):3868-76
   PubMed Web of Science ®Google Scholar
• Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011;332(6035):1317-22
   PubMed Web of Science ®Google Scholar
• Sodhi A, Montaner S, Patel V, et al. Akt plays a central role in sarcomagenesis induced by Kaposi’s sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 2004;101(14):4821-6
   PubMed Web of Science ®Google Scholar
• Sodhi A, Chaisuparat R, Hu J, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006;10(2):133-43
   PubMed Web of Science ®Google Scholar
• Roy D, Dittmer DP. Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi’s sarcoma. Am J Pathol 2011;179(4):2108-19
   PubMed Web of Science ®Google Scholar
• Petricoin EF III, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007;67(7):3431-40
   PubMed Web of Science ®Google Scholar
• Kaylani SZ, Xu J, Srivastava RK, et al. Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model. Biochem Biophys Res Commun 2013;435(4):557-61
   PubMedGoogle Scholar
• Italiano A, Chen CL, Thomas R, et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 2012;118(23):5878-87
   PubMedGoogle Scholar
• Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005;102(24):8573-8
   PubMed Web of Science ®Google Scholar
• Johansson G, Mahller YY, Collins MH, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 2008;7(5):1237-45
   PubMed Web of Science ®Google Scholar
• Reis H, Hager T, Wohlschlaeger J, et al. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma. Hum Pathol 2013;44(10):2266-74
   PubMedGoogle Scholar
• Setsu N, Kohashi K, Fushimi F, et al. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma. Cancer 2013;119(19):3504-13
   PubMed Web of Science ®Google Scholar
• Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358(2):140-51
   PubMed Web of Science ®Google Scholar
• Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011;17(12):4071-81
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010;28(5):835-40
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK, Antonescu CR, et al. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer 2013;132(7):1711-17
   PubMed Web of Science ®Google Scholar
• Schöffski P, Reichardt P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010;21(10):1990-8
   PubMed Web of Science ®Google Scholar
• Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):1317-23
   PubMed Web of Science ®Google Scholar
• Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 2011;117(15):3468-75
   PubMed Web of Science ®Google Scholar
• Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012;30(1):78-84
   PubMed Web of Science ®Google Scholar
• Yoo C, Lee J, Rha SY, et al. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Invest New Drugs 2013;31(6):1602-8
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Zhao L, Chugh R, et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer 2012;48(9):1347-53
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013;14(4):371-82
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817-24
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31(19):2485-92
   PubMed Web of Science ®Google Scholar
• Choo AY, Yoon SO, Kim SG, et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008;105(45):17414-19
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013;39(4):313-20
   PubMedGoogle Scholar
• Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011;30(29):3222-33
   PubMedGoogle Scholar
• Nogová L, Boellaard R, Kobe C, et al. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med 2009;50(11):1815-19
   PubMedGoogle Scholar
• Ma WW, Jacene H, Song D, et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27(16):2697-704
   PubMed Web of Science ®Google Scholar
• Yamnik RL, Digilova A, Davis DC, et al. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 2009;284(10):6361-9
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
   PubMed Web of Science ®Google Scholar
• De Raedt T, Walton Z, Yecies JL, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 2011;20(3):400-13
   PubMed Web of Science ®Google Scholar
• Faber AC, Coffee EM, Costa C, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 2014;4(1):42-52
   PubMedGoogle Scholar